CellOrigin Biotech
PrivateLast Round
Early Funding
Sep 21, 2023
Total Funding Raised
$13.8M
Company Overview
CellOrigin Biotech is a biotechnology company that develops genetically engineered iPSC-derived immune cell therapies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CellOrigin Biotech Comparables
Compare CellOrigin Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shoreline Biosciences | 89% | |
| Neukio Biotherapeutics | 87% | |
| RocRock Biotechnology | 84% |
CellOrigin Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Sep 21, 2023 | ||||
| Early Funding | Feb 16, 2022 | ||||
| Angel | Jul 16, 2021 |
CellOrigin Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jifeng Ventures | Early Funding |
| Nest.Bio | Angel |
| Kunlun Capital | Angel |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 7, 2025
Monthly visitors increased 1574% MoM, from 19 to 318.
- Sep 21, 2023
Completed an early funding round.
Recent news
Latest coverage and updates
- attends_eventJul 31, 2026
Cell Origin attended event 2026 ASCO Annual Meeting on Jul 31st '26.
- partners_withJul 31, 2026
Cell Origin partnered with Walvax Biotechnology Co. on Jul 31st '26.
- attends_eventJul 31, 2026
Cell Origin attended event ASCO 2026 on Jul 31st '26.
- launchesJul 31, 2026
Cell Origin launched two novel solid-tumor cell therapy candidates at ASCO 2026 on Jul 31st '26.
CellOrigin Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CellOrigin Biotech's valuation, stock price, and market status.
Is CellOrigin Biotech a public or private company?
CellOrigin Biotech is a private company.
What is the current stock price of CellOrigin Biotech?
CellOrigin Biotech is a private company with no public stock price. No recent secondary market data is available.
How much is CellOrigin Biotech worth (valuation)?
Valuation information for CellOrigin Biotech is not publicly available.
Can I buy CellOrigin Biotech stock?
CellOrigin Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was CellOrigin Biotech's last funding round?
CellOrigin Biotech's most recent funding round was Early Funding on September 21, 2023.
Who are the main investors in CellOrigin Biotech?
Key investors in CellOrigin Biotech include Jifeng Ventures, Kunlun Capital.
Will CellOrigin Biotech IPO soon?
No public IPO plans have been announced for CellOrigin Biotech.
How can I track CellOrigin Biotech secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CellOrigin Biotech's secondary market activity and sign up for updates.